The absence of CD58 correlates with immune evasion and pharmacological resistance in hematological malignancies, including leukemia and lymphoma, and is a unique biomarker for forecasting clinical outcomes in the new era of immunotherapy. The gene discussed is CD58; the disease is leukemia.